Nanobiotix S.A. ADR (NBTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NBTX Stock Summary
- NANOBIOTIX SA's stock had its IPO on December 11, 2020, making it an older stock than just 9.39% of US equities in our set.
- With a price/sales ratio of 58.4, NANOBIOTIX SA has a higher such ratio than 96.66% of stocks in our set.
- Revenue growth over the past 12 months for NANOBIOTIX SA comes in at -12.16%, a number that bests just 12.23% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to NANOBIOTIX SA are LCTX, BGRY, IMV, PTN, and ANGN.
- To check out NANOBIOTIX SA's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001760854.
NBTX Stock Price Chart Interactive Chart >
NBTX Price/Volume Stats
|Current price||$4.49||52-week high||$9.13|
|Prev. close||$4.45||52-week low||$2.32|
|Day high||$4.49||Avg. volume||1,100|
|50-day MA||$3.93||Dividend yield||N/A|
|200-day MA||$5.02||Market Cap||156.59M|
Nanobiotix S.A. ADR (NBTX) Company Bio
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
Most Popular Stories View All
NBTX Latest News Stream
|Loading, please wait...|
NBTX Latest Social Stream
View Full NBTX Social Stream
Latest NBTX News From Around the Web
Below are the latest news stories about NANOBIOTIX SA that investors may wish to consider to help them evaluate NBTX as an investment opportunity.
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisable
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
Patients randomized in all planned major regions for pivotal phase 3 NANORAY-312 study with the United States added to Europe and AsiaNANORAY-312 now has sites activated across 80 sites globallyPhase 3 futility analysis expected in 2H 2023, with interim Phase 3 data expected in 2H 2024 PARIS and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expa
PARIS and CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it has ended the liquidity contract signed on October 23, 2012 with Gilbert Dupont. The termination is effective from December 20th, 2022, after the close of Euronext market. On the termination date of this contrac
PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on Thursda
Data show that radiotherapy-activated NBTXR3 was feasible and well tolerated in the complete dose escalation part of a Study 2019-1001, a phase 1 evaluation of NBTXR3 for patients with locally advanced pancreatic adenocarcinomaThe recommended phase 2 dose for radiotherapy-activated NBTXR3 in pancreatic cancer was established at 42% of gross tumor volume and the dose expansion part of the study is ongoing in the United StatesThe company expects to report safety and early efficacy data from the es
NBTX Price Returns